TTD | Drug: D04AIB

Drug General Information
Drug ID	D04AIB
Former ID	DIB014250
Drug Name	AZD1772//RDX5791
Indication	Chronic kidney disease [ICD9: 403, 585.1-585.5, 585.9; ICD10:N18]		Phase 2	[550265]
Company	Ardelyx; astrazeneca
Target and Pathway
Target(s)	Sodium/hydrogen exchanger 3	Target Info	Modulator	[550792]
KEGG Pathway	Proximal tubule bicarbonate reclamation
	Protein digestion and absorption
	Bile secretion
	Mineral absorption
Pathway Interaction Database	Endothelins
Pathway Interaction Database	RhoA signaling pathway
WikiPathways	SIDS Susceptibility Pathways
References
Ref 550265	Clinical pipeline report, company report or official report of Ardelyx.
Ref 550792	RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information